Results 81 to 90 of about 6,898 (217)
Clinical Pharmacology &Therapeutics, Volume 119, Issue 6, Page 1565-1573, June 2026.There is a paucity of data regarding the effects of prenatal disease‐modifying therapies (DMTs) for multiple sclerosis (MS), on congenital anomalies in the offspring. Moreover, data on the association with neurodevelopmental disorders are lacking. This is an historical cohort study, within the Israeli Clalit Health Services database (2005–2024) that ...
Bar Rosh +4 more
wiley +1 more source
Lysophospholipid correlations with lutein in human infant brain.a
, 2015 aSubject ages ranged from 1 to 488 days old, and the median age was 100.5 days. 30 total decedents were studied and included both male (n = 21) and female (n = 9) infants.
Elizabeth J. Johnson (789437) +4 more
core +1 more source
Journal of Clinical Laboratory Analysis, Volume 40, Issue 12, June 2026.This study utilizes a two‐sample Mendelian randomization framework to establish a causal link between circulating inflammatory proteins, blood metabolites, and the risk of serous ovarian carcinoma. Our findings identify Interleukin‐8 as a significant risk factor and demonstrate that 1‐Palmitoyl‐GPG (16:0) acts as a metabolic mediator within this ...
Chong‐ze Yang +6 more
wiley +1 more source
JOR SPINE, Volume 9, Issue 2, June 2026.LMP is responsible for lysosomal dysfunction in IDD. The lipid composition changes in the lysosomal membrane, mediated by PLA2G15, are the cause of LMP. The C/EBPα significantly promotes PLA2G15 expression under PA overload stress. Inhibition of PLA2G15 alleviates PA‐induced LMP by inhibiting the hydrolysis of lysosomal membrane phospholipids. ABSTRACT
Liqun Duan +7 more
wiley +1 more source
, 2011 Research in the author's laboratory is supported in part by a Wellcome Trust Senior Research Fellowship (067441), and Wellcome Trust project grants (086658 and 093228) and a Wellcome Trust Prize Studentship (G.S.R).Phospholipase A1 (PLA1) is an enzyme ...
Smith, Terry K. +3 more
core +1 more source
Unveiling the Power of Deuterium in Drug Discovery: A Comprehensive Overview
MedComm, Volume 7, Issue 6, June 2026.The role of deuterium replacement in drug discovery, its progress, opportunities, and challenges. ABSTRACT Deuterium, the heavy isotope of hydrogen, has unfolded as a cornerstone in modern drug discovery due to its potential to influence metabolic stability and pharmacokinetic behavior.
Mukta Lele +7 more
wiley +1 more source
, 2010 Eric Birgbauer, Jerold ChunDepartment of Molecular Biology, Helen L Dorris Institute for Neurological and Psychiatric Disorders, The Scripps Research Institute, La Jolla, CA, USA Abstract: One of the major requirements in the development of the visual ...
Eric Birgbauer, Jerold Chun
core
Dysregulated Lipid Metabolism in Hepatocellular Carcinoma: Mechanisms and Therapeutic Strategies
MedComm – Oncology, Volume 5, Issue 2, June 2026.Dysregulated lipid metabolism facilitates hepatocellular carcinoma (HCC) development, progression, immunosuppressive tumor microenvironment (TME) formation, and therapeutic resistance. Notably, the patterns of lipid metabolism vary significantly among different types of HCC driven by various etiologies.
Yi Yi +4 more
wiley +1 more source
Lysophospholipid (S1P) receptors (version 2020.5) in the IUPHAR/BPS Guide to Pharmacology Database
, 2020 Sphingosine 1-phosphate (S1P) receptors (nomenclature as agreed by the NC-IUPHAR Subcommittee on Lysophospholipid receptors [86]) are activated by the endogenous lipid sphingosine 1-phosphate (S1P). Originally cloned as orphan members of the endothelial
Blaho, Victoria +5 more
core +1 more source
Differential lipid metabolism in monocytes and macrophages: influence of cholesterol loading[S]
Journal of Lipid Research, 2016 The influence of the hypercholesterolemia associated with atherosclerosis on monocytes is poorly understood. Monocytes are exposed to high concentrations of lipids, particularly cholesterol and lysophosphatidylcholine (lyso-PC).
Irene Fernandez-Ruiz +4 more
doaj +1 more source